Stock Upgrades Today

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  10 Feb 2026
 

•   ACM  
   
  -1.95%
•   AMD  
   
  -0.73%
•   APP  
   
  +0.74%
•   ARES  
   
  +0.21%
•   AVGO  
   
  -0.47%

$ACM traded higher after BofA Securities nudged its price target up to $118, reinforcing a constructive stance as infrastructure and engineering demand remain firm. With shares around $104 and volume running above average, the incremental target hike suggests analysts still see room for multiple expansion tied to public spending tailwinds.

$AMD remains a focal point in the AI arms race. Goldman Sachs reiterated a Neutral rating, flagging datacenter momentum but also highlighting operating expense pressure. Even with the stock hovering near $214 and pulling back modestly, the Street appears divided between near-term margin concerns and longer-term AI accelerator upside.

$APP is drawing renewed attention after Jefferies reiterated its Buy rating and $860 price target, calling the recent sell-off a disconnect between fundamentals and valuation. At $472, shares are well below that target, and the firm conviction signals confidence in the monetization engine despite volatility.

$ARES delivered one of the clearest bullish signals of the day. Deutsche Bank upgraded the stock from Hold to Buy, while Raymond James moved from Market Perform to Strong Buy, both pointing to roughly 45% upside. Even with shares slightly lower near $137, dual upgrades from major firms reinforce the narrative of accelerating fee-related earnings and capital deployment.

$AVGO saw UBS reiterate its Buy rating with a $475 target. With shares around $341, the call underscores continued confidence in Broadcom AI-exposed semiconductor and infrastructure software mix, even as the stock digests prior gains.

$BRBR had its price target lowered by UBS while maintaining a Neutral stance. At $18.50 and trading below average volume, the message is more about tempered expectations than a shift in long-term fundamentals.

$CAT appears in broader bullish commentary around industrial upside. While details were limited, the tone around potential double-digit rally prospects keeps the heavy equipment giant on traders’ radar as a cyclical play tied to global capex.

$CCI is benefiting from a risk-reward reset, with an upgrade to Buy reflecting improving turnaround dynamics. At roughly $85 and rebounding over 2%, the telecom REIT is being viewed as a recovery candidate as operational execution stabilizes.

$CHWY maintained its Overweight rating from Piper Sandler. The steady endorsement, even with muted price action, suggests confidence in margin trajectory and customer engagement metrics despite competitive e-commerce pressures.

$CPNG saw Bernstein initiate coverage with an Underperform rating and a $17 target, slightly below current levels. The cautious tone implies valuation and competitive intensity concerns in the Korean e-commerce landscape.

$DASH gained attention as Goldman Sachs added it to its US Conviction list while UBS adjusted its target higher but kept a Neutral rating. Around $185, the stock reflects improving sentiment on delivery economics and scale advantages.

$DOCS was upgraded from Hold to Buy by Canaccord Genuity, with analysts pointing to significant upside potential. Trading near $27, the call signals belief that Doximity physician network and ad model can reaccelerate growth.

$GPRE moved to Overweight at Stephens, though projected downside in the target suggests a more nuanced view. The nearly 5% pop to $15 indicates traders are reacting to the rating change despite mixed forecast implications.

$MBOT surged over 16% after B. Riley initiated coverage with a Buy rating. With volume vastly exceeding average levels, the small-cap medical device name is seeing speculative interest tied to commercialization potential.

$MCD continues to expand internationally, with Malaysia investment plans highlighting long-term unit growth. While not a classic upgrade call, the capital commitment reinforces the defensive growth thesis at $326.

$MDT was upgraded from Hold to Buy by Needham, implying roughly 10% upside. At $101, Medtronic steady cash flows and product pipeline improvements are attracting renewed institutional support.

$META remains a compounding story, cited by investment managers for its 2025 performance. Despite a modest pullback near $671, the narrative around AI monetization and ad resilience remains intact.

$NVO had its price target trimmed by BofA while maintaining a Neutral stance, reflecting weaker 2026 guidance. At $49, sentiment appears cautious as investors recalibrate growth expectations.

$O continues to benefit from analyst optimism, including upgrades tied to its strategic partnership initiatives. Trading around $64, Realty Income diversified capital strategy is resonating with REIT-focused investors.

$ORCL received a notable upgrade from DA Davidson, moving from Neutral to Buy with substantial implied upside. Shares near $160 and elevated volume reflect growing confidence in Oracle cloud and AI infrastructure positioning.

$PLD maintained a Buy rating at Truist despite a slight target cut. Around $140, Prologis remains a preferred industrial REIT play as logistics demand underpins long-term occupancy.

$PLTR was upgraded by Daiwa on strong AI-driven commercial momentum, with a $180 target suggesting about 26% upside. Despite a recent pullback to $138, Palantir continues to attract high-volume interest.

$QCOM reiterated its Overweight rating at Piper Sandler after beating estimates. At roughly $140, Qualcomm AI handset and automotive exposure are key drivers behind sustained analyst support.

$RPRX was upgraded to Buy by UBS with a raised price target, reinforcing bullish healthcare royalty dynamics. Near $44, the firm sees improved capital allocation and deal flow.

$SAN is approaching analyst target levels, a scenario that often triggers reassessment. The recent downgrades reflect valuation concerns as shares trade above prior consensus targets.

$SMCI maintained a Buy rating at Rosenblatt following a strong quarter. At $33, the stock remains highly volume-driven, with AI server demand anchoring the bull case.

$SOFI was upgraded to Market Outperform by Citizens, with analysts projecting nearly 28% upside. Despite a slight dip to $21, strong member growth and product expansion continue to attract bullish revisions.

$SPG saw its price target raised by JPMorgan while maintaining a Neutral rating. Trading near $197, the mall REIT is balancing record FFO performance with valuation discipline.

$STNE has crossed above average analyst targets, often a precursor to rating adjustments. At $17.84, the move suggests the market may be pricing in improved fintech fundamentals ahead of the Street.

$TEVA maintained an Overweight stance at Barclays with a higher target, reflecting confidence in earnings trajectory post-results. Around $34, the turnaround thesis remains in play.

$TTD continues to draw long-term investor interest, highlighted in fund commentary. With shares up over 4% to $28, digital ad spend recovery and platform leverage remain central themes.

$U was upgraded by B. Riley, lifting sentiment as shares rallied more than 4% to $28.72. The call points to stabilization in gaming and monetization trends after prior volatility.

$VICI faced a downgrade to Sector Perform, signaling more tempered expectations despite its REIT appeal. At $29, yield support remains but upside appears capped in the near term.

$VTRS received a price target update while maintaining a Neutral stance, reflecting incremental adjustments rather than a decisive shift in outlook. Shares around $16 suggest a wait-and-see approach from analysts.

$WULF gained attention as Morgan Stanley began coverage on bitcoin miners with an Overweight view on select names. At $17 and trading well above average volume, the infrastructure and AI-adjacent angle is fueling speculative interest.

View All Headlines